Bausch + Lomb Corp., the maker of contact lenses and various eyecare products, has filed to go public in the U.S. and Canada through an initial public offering (IPO).
The unit of Bausch Health Co. said in a regulatory filing that it would seek to raise $100 million U.S., a placeholder amount that will most likely change.
Bausch + Lomb is seeking to list shares on both the New York and Toronto Stock Exchanges under the ticker symbol “BLOO.”
The listing will involve only existing shares and no new shares will be offered, according to the regulatory filing.
Founded in 1853 by John Bausch and Henry Lomb in Rochester, New York, the optical products maker reported $2.8 billion U.S. in revenue in the nine months ended September 2021, up 12% from the same period a year earlier. The company’s net income shrunk to $131 million U.S. from $191 million U.S.
Investment banks Morgan Stanley (MS) and Goldman Sachs (GS) are the lead advisors on the IPO.
